Multiple 'First-in-Asia' Pharmaceutical and Healthcare Projects Land in Beijing in 2025

Xinhua News Agency, Beijing, October 25th (Reporter Chen Hang) — On the 25th, it was learned from the 2025 International Biomedical Industry Innovation Beijing Forum that this year, several key projects, which are the first of their kind in Asia and China, have been established in Beijing Economic-Technological Development Area (referred to as "Beijing Yizhuang").

All of the above projects are located in BioPark, the International Pharmaceutical Innovation Park in Beijing's Yizhuang area. Among them, Johnson & Johnson plans to build the first innovation center in Asia at BioPark, the largest medical device training center in the Asia-Pacific region, a global electrophysiology application and training center, and the Johnson & Johnson China Digital Innovation Center; GE Healthcare intends to establish the second-largest global medical equipment R&D center, as well as China’s first imaging equipment innovation incubator; Philips will construct the second headquarters for its full product line R&D center globally, along with a Sino-Dutch and Sino-European International Academic Center, and will jointly build a physician training center; Sino Biopharmaceutical Co., Ltd. will establish its first cutting-edge technology innovation R&D center.

On October 25, AstraZeneca Global R&D Beijing Strategic Center was officially launched. This center is the second global strategic R&D center established by AstraZeneca in China after the establishment of AstraZeneca Global R&D Shanghai Strategic Center. (Photo by Fu Tian, China News Service)

On the 25th, AstraZeneca Global R&D Beijing Strategic Center was officially launched. This center is the second global strategic R&D center established by AstraZeneca in China after the establishment of AstraZeneca Global R&D Shanghai Strategic Center. It will lead new drug discovery and clinical development through collaborative efforts, accelerating the transformation of innovative achievements into life-changing medicines. At the same time, it will actively expand cooperation with local clinical trial institutions, universities, and biotech companies to deepen disease understanding and incubate scientific innovations.

At the conference, the BioPark planning proposal was officially released. The park is located along the southern central axis of Beijing. According to the plan, BioPark will feature four major industrial functional zones: a headquarters cluster area, a medical-engineering integration zone, a research and development transformation zone, and a pharmaceutical intelligent manufacturing zone. Among these, the headquarters cluster area will focus on becoming an international hub for pharmaceutical industry exchange, providing high-quality international business spaces to serve the landing of top global biopharmaceutical company headquarters and innovation centers. The pharmaceutical intelligent manufacturing zone will gather "lighthouse" factories for pharmaceutical smart manufacturing, attracting the industrialization of globally significant innovative products.

As an important承载区 for Beijing's pharmaceuticals and healthcare industry, Beijing Yizhuang has already gathered over 5,000 biopharmaceutical companies, establishing a complete industrial chain system from R&D, production, services to sales. The next step for Beijing Yizhuang is to advance the construction of BioPark, attracting more leading enterprises, research institutions, and top scientists. It aims to achieve a breakthrough of 120 billion yuan in pharmaceuticals and healthcare industrial output by 2027, creating an innovation highland with global influence. (END)